KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Convertible Debt: 2020-2024

Historic Convertible Debt for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to $96.7 million.

  • Esperion Therapeutics' Convertible Debt fell 63.06% to $97.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.1 million, marking a year-over-year decrease of 63.06%. This contributed to the annual value of $96.7 million for FY2024, which is 63.02% down from last year.
  • Esperion Therapeutics' Convertible Debt amounted to $96.7 million in FY2024, which was down 63.02% from $261.6 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Convertible Debt ranged from a high of $261.6 million in FY2023 and a low of $96.7 million during FY2024.
  • Moreover, its 3-year median value for Convertible Debt was $259.9 million (2022), whereas its average is $206.1 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first surged by 44.00% in 2021, then plummeted by 63.02% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Convertible Debt stood at $179.4 million in 2020, then spiked by 44.00% to $258.3 million in 2021, then rose by 0.63% to $259.9 million in 2022, then climbed by 0.65% to $261.6 million in 2023, then plummeted by 63.02% to $96.7 million in 2024.